Table 9. Oral Contraceptive (OC) Use and Breast Cancer Risk in BRCA1/BRCA2 Mutation Carriers
| Brohet 2007a [100] | Haile 2006b,c [101] | Narod 2002b [102] | ||
| Study Population | BRCA1 Carriers with Breast Cancer | N = 597 | N = 195; diagnosis < age 50 y | N = 981 |
| BRCA2 Carriers with Breast Cancer | N = 249 | N = 128; diagnosis < age 50 y | N = 330 | |
| Ever Use OC | BRCA1 | 1.47 [CI 1.13–1.91] | 0.64 [CI 0.35–1.16] | 1.38 [CI 1.11–1.72] P = .003a |
| BRCA2 | 1.49 [Cl 0.8–2.7] | 1.29 [Cl 0.61–2.76] | 0.94 [Cl 0.72–1.24] | |
| Age Use < 20 y | BRCA1 | 1.41 [Cl 0.99–2.01] | 0.84 [Cl 0.45–1.55] | 1.36 [Cl 1.11–1.67] P = .003 |
| BRCA2 | 1.25 [Cl 0.57–2.74] | 1.64 [Cl 0.77–3.46] | Not reported | |
| Total Duration | BRCA1 | <9 y: 1.51 [Cl 1.1–2.08] | <5 y: 0.61 [Cl 0.31–1.17] | <10 y: 1.36 [Cl 1.11–167] P = .003 |
| BRCA2 | <9 y: 2.27 [Cl 1.1–4.65] | <5 y: 0.79 [Cl 0.26–2.37] | <10 y: 0.82 [Cl 0.56–1.91] | |
| Use Before Full-term Pregnancy | BRCA1 | >4 y: 1.49 [Cl 1.05–2.11] | >4 y: 0.69 [Cl 0.41–1.16] | Not evaluated |
| BRCA2 | >4 y: 2.58 [Cl 1.21–5.49] | >4 y: 2.08 [Cl 1.02–4.25] trend per y: 1.11; P trend = .01 | ||
| Use Before 1975 | BRCA1 | 1.48 [Cl 1.11–1.98] | Excluded patients who used OC before 1975 | 1.42 [Cl 1.17–1.75] P < .001 Not evaluated |
| BRCA2 | 1.36 [Cl 0.71–2.58] | |||
| Use After 1975 | BRCA1 | 1.57 [Cl 1.11–2.22] | 0.65 [Cl 0.36–1.19] | |
| BRCA2 | 1.53 [Cl 0.75–3.12] | 1.21 [Cl 0.56–2.58] | ||
| CI = confidence interval. | |
| aReports risk estimates in the form of hazard ratios with 95% confidence intervals. | |
| bReports risk estimates in the form of odds ratios with 95% confidence intervals. | |
| cRisk estimates restricted to BRCA mutation carriers younger than 40 years. |
References
- Brohet RM, Goldgar DE, Easton DF, et al.: Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol 25 (25): 3831-6, 2007. [PUBMED Abstract]
- Haile RW, Thomas DC, McGuire V, et al.: BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev 15 (10): 1863-70, 2006. [PUBMED Abstract]
- Narod SA, Dubé MP, Klijn J, et al.: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94 (23): 1773-9, 2002. [PUBMED Abstract]
